BioCryst公司的贝罗司他胶囊用药注意事项

Orladeyo has been approved by the U.S. Food and Drug Administration (FDA) for the prevention of hereditary angioedema (HAE) attacks in pediatric and adult patients ≥12 years of age. Berostat capsule Orladeyo is the first targeted oral therapy approved to prevent HAE attacks. The approval of berostat capsule Orladeyo will bring significant progress in the treatment of HAE patients with hereditary angioedema and will help reduce the treatment burden on patients.

BioCryst Corporation is a biotechnology company. BioCryst designs, optimizes and develops small molecule drugs that block enzymes involved in disease pathogenesis. The company focuses on treating rare diseases. BioCryst uses X-ray scattering technology, molecular structure computer simulations and chemical techniques to focus on the three-dimensional molecular structure and active site characteristics of enzymes that control cell biology.

The therapeutic effect of berostat capsule Orladeyo is very significant, and the successful development of this drug is good news for many patients. However, patients are not allowed to use Orladeyo capsules for treatment without authorization. Orladeyo treatment will also produce certain side effects or adverse reactions. The most common adverse reactions include: abdominal pain/vomiting/diarrhea/back pain/gastroesophageal reflux disease, etc.

Precautions when taking BioCryst’s berosostat capsules:

Advise patients not to take oral doses of Orladeyo in excess of 150 mg once daily or additional doses of Orladeyo capsules to treat hereditary angioedema HAE acute attacks due to the risk of QT prolongation.

Patients who are allergic to any of the ingredients in Berostat capsule Orladeyo should not use this drug for treatment.

Orladeyo should be stored at 20ºC to 25ºC (68ºF to 77ºF). The allowed offset range is 15ºC to 30ºC (59ºF to 86ºF).

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.